SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Abhimanyu Verma Sells 5,284 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,284 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $8.12, for a total transaction of $42,906.08. Following the completion of the transaction, the chief technology officer directly owned 166,887 shares in the company, valued at $1,355,122.44. This represents a 3.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Monday, August 24th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.80, for a total transaction of $44,000.00.
• On Wednesday, August 19th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.20, for a total transaction of $41,000.00.
• On Friday, August 7th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.60, for a total transaction of $38,000.00.
• On Tuesday, August 4th, Abhimanyu Verma sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.95, for a total transaction of $34,750.00.

SOPHiA GENETICS Price Performance

NASDAQ SOPH opened at $7.30 on Friday. SOPHiA GENETICS SA has a 1 year low of $3.75 and a 1 year high of $8.98. The business’s fifty day moving average is $7.88 and its two-hundred day moving average is $6.15. The stock has a market capitalization of $612.40 million, a P/E ratio of -6.35 and a beta of 0.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The company had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, research analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of large investors have recently made changes to their positions in SOPH. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter worth approximately $9,809,000. Principal Financial Group Inc. grew its position in SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in SOPHiA GENETICS during the first quarter valued at approximately $2,157,000. Sei Investments Co. acquired a new position in SOPHiA GENETICS in the 1st quarter valued at approximately $1,772,000. Finally, 1492 Capital Management LLC lifted its position in SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock worth $1,117,000 after buying an additional 17,406 shares in the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Myriad Genetics and SOPHiA GENETICS are partnering with AstraZeneca to use prostate cancer technology involving genomic-instability scoring. The agreement provides potential commercial and validation benefits for SOPH by connecting its analytics capabilities with Myriad’s testing expertise and AstraZeneca’s oncology development programs. Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
• Positive Sentiment: The collaboration reinforces SOPHiA GENETICS’ positioning in cancer genomics and could increase adoption of its cloud-based SOPHiA DDM platform. However, the reports do not disclose financial terms, revenue guidance or a specific near-term contribution, so the immediate earnings impact remains uncertain. SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
• Neutral Sentiment: Several executives and directors, including the CEO, chairman, CFO and CTO, sold shares at approximately $8.04–$8.13. The sales were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial position. SOPHiA GENETICS insider trading report
• Negative Sentiment: The broad group of insider sales totaled roughly $669,000 and may create some near-term selling pressure or investor caution, despite the transactions appearing administrative rather than discretionary bearish bets.

Analysts Set New Price Targets

SOPH has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research raised their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. HC Wainwright raised their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.